Entering text into the input field will update the search result below

Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate

Jul. 07, 2022 7:45 AM ETAnnovis Bio, Inc. (ANVS)VERUBy: Dulan Lokuwithana, SA News Editor4 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Clinical-stage biotech Annovis Bio (NYSE:ANVS) added ~10% in the pre-market Thursday after the company announced that the FDA gave the go-ahead to a Phase 3 trial for oral experimental therapy buntanetap for

Recommended For You

Comments (4)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Great news! Now lets see it reflected in the price action
@dealripper ...sustainably
TJ Burke profile picture
Bought in a few weeks ago - working so far. Finish line still far off - as with SAVA and AVXL
PFD profile picture
07 Jul. 2022
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.